Express Pharma
DECEMBER 16, 2024
On December 13, 2024, Lupin, a global pharmaceutical company, announced the acquisition of anti-diabetes trademarks GIBTULIO, GIBTULIO MET, and AJADUO from Boehringer Ingelheim International GmbH. The move is aimed at strengthening Lupins diabetes portfolio in India. In addition, 25 million people are pre-diabetic.
STAT
MARCH 3, 2025
More than a decade ago, Ken Mandl was on a call with a pharmaceutical company and the leader of a social network for people with diabetes. The drug maker was hoping to use the platform to encourage its members to get a certain lab test. The test could determine a patient’s need for a helpful drug.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
FEBRUARY 6, 2024
The blockbuster weight loss and diabetes drug sold by Eli Lilly also appears to improve fatty liver disease, according to early clinical trial data the pharmaceutical company released Tuesday.
STAT
NOVEMBER 18, 2022
… Pharmaceutical companies could be made to disclose prices and deals for products they make to fight future global health emergencies, under new rules that would govern a World Health Organization-backed pandemic accord , Reuters reports. The first therapy that delays the onset of type 1 diabetes received approval from the U.S.
STAT
MAY 20, 2024
For more than a year, Sanders has used his perch atop the Senate health committee to haul the CEOs of pharmaceutical companies that make insulin, vaccines, and more before the panel with progressively more ambitious demands related to their pricing. Sanders (I-Vt.)
STAT
SEPTEMBER 28, 2023
The Danish pharmaceutical company Novo Nordisk has shepherded all kinds of medical innovation in the 110 years since it was founded. But the booming success of its diabetes and obesity drug is unlike anything executives have seen before. The company’s mid-year operating profit jumped from 37.5
STAT
FEBRUARY 5, 2024
billion deal, an acquisition that will give Novo additional sites as it builds up production of its booming obesity and diabetes drugs. Under the deal, Novo Holdings is purchasing Catalent, a major contract development and manufacturing company with more than 50 sites globally.
Expert insights. Personalized for you.
105 
Let's personalize your content